<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969039/" ref="ordinalpos=1310&amp;ncbi_uid=6012688&amp;link_uid=PMC3969039" image-link="/pmc/articles/PMC3969039/figure/f2-molcell-37-3-196-2/" class="imagepopup">Fig. 2. From: Apelin-APJ <span class="highlight" style="background-color:">Signaling</span>: a Potential Therapeutic Target for Pulmonary Arterial Hypertension. </a></div><br /><div class="p4l_captionBody">Putative model of the mechanism of vascular homeostasis mediated by apelin-APJ signaling. (A) Basal apelin-APJ signaling maintains expression of miR-424/503, KLF2, and eNOS, as well as activity of AMPK. miR-424/503 in turn inhibits FGF2/FGFR1 expression, and eNOS induces the production of NO. (B) In PAH, there is decreased apelin, miR-424/503 and eNOS expression, leading to abnormal activation of FGF signaling pathway and reducing NO level that target both the PAECs and PASMCs.</div></div>